Navigation Links
Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis
Date:1/28/2009

Golimumab Will Earn Decision Resources' Gold Standard for Rheumatoid Arthritis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists say that a therapy's effect on reducing the signs and symptoms of rheumatoid arthritis at one year is the attribute that most influences their prescribing decisions in treating the disease. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over Amgen/Wyeth/Takeda's Enbrel (etanercept), the market sales-leading agent.

The new report entitled Rheumatoid Arthritis: A Novel Oral Therapy Must Satisfy Physicians' High Expectations for Efficacy to Tap Significant Market Opportunity finds that an oral disease-modifying drug with a novel mechanism of action that is priced 20 percent lower than etanercept plus methotrexate would earn a 25 percent patient share in the United States and a 20 percent patient share in Europe, according to surveyed U.S. and European rheumatologists.

Decision Resources' proprietary clinical gold standard in 2008 for rheumatoid arthritis was Enbrel, most notably because of its superior efficacy in inhibiting/slowing structural damage progression at one and two years compared with other agents in the market. Following its approval for the indication, which is likely to occur in 2010, Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi (golimumab) will earn Decision Resources' gold standard for rheumatoid arthritis in 2012. Although Simponi's overall efficacy, safety and tolerability do not match that of Enbrel, its advantages in delivery differentiate it from Enbrel.

"Simponi ranks higher than Enbrel on the measures of dosage formulation and d
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
3. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
4. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
5. Experimental drug boosts survival in recurrent ovarian cancer
6. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
7. Stop eating for two: obese moms-to-be should gain less weight than currently recommended
8. Switching to MA Coverage Unlikely for Current Beneficiaries With MediGap or Medicare Only
9. The Current Recall of Boy Scouts of Americas Plastic Badges Does Not Affect Embroidered Insignia, Badges & Awards Produced by Lion Brothers Company Inc.
10. Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women!
11. ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 The Journal of Parasitology ... today’s computer software, it creates questions of ethics. For ... As an already published case shows, scientific publications need ... The Journal of Parasitology features a ... a 2004 article published in the Journal of the ...
(Date:6/19/2013)... HOUSTON - In a major international study led by ... Center, the targeted therapy ibrutinib continues to show remarkable ... cell lymphoma (MCL). , The most recent interim findings ... in the New England Journal of Medicine . ... the 54th American Society of Hematology Annual Meeting and ...
(Date:6/19/2013)... published in the June 19 online edition of the ... researchers from the University of California, San Diego School ... take place when cardiac regeneration occurs in zebrafish after ... various cell lines in the heart are more plastic, ... previously thought. , More importantly, the research reveals a ...
(Date:6/19/2013)... understanding of the genetic process that can lead to ... lesions for some women, and also raises a warning ... cases suggesting they could actually trigger the cancer ... a clearer picture of the chromosomal and genetic changes ... to chronic infection and, in less than 1 percent ...
(Date:6/19/2013)... University of Iowa study reveals significant disparities between ... completing substance abuse treatment programs. Moreover, these disparities ... "Our findings suggest that for most states there,s ... of psychiatry and biostatistics. "There are strong racial ... to complete substance abuse treatment programs successfully, and ...
Breaking Medicine News(10 mins):Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... out-of-pocket health care costs, CAMP HILL, Pa., Sept. ... to help consumers compare health plan options and,choose one ... is available,to consumers on Highmark member Web sites. ... said Kim,Bellard, Vice President of eMarketing and Customer Relationship ...
... President, SEIU-UHW and SEIU California State ... ... My name is Sal Rosselli,and I,m the President of SEIU United ... workers in healthcare, the,public sector, property services, and other industries throughout ...
... choices , MONDAY, Sept. 10 (HealthDay News) -- U.S. and ... a comprehensive recommendation on how much of what types of ... diets. , Both the American Dietetic Association and the Dietitians ... that 20 percent to 30 percent of energy needs should ...
... -- In lifesaving procedures to open blocked heart arteries ... use of the more expensive drug, abciximab, justified over ... Mayo Clinic study to be published in the current ... and now available as an e-publication, offers clinicians the ...
... Hundreds of Institutional Investors to Attend Conference, ... Board: SKVI / Website: http://www.skinvisible.com ), the ... topically,applied dermatology products, today announced that Mr. Terry ... annual Merriman Curhan Ford & Co.,Investor Summit on ...
... Through November 2007 -, GLENDALE, Calif., ... for applications for the 2008-2009 PowerBar Team ... athletes, coaches,nutritionists, trainers and health and fitness ... invited to visit, http://www.powerbar.com/teamelite/application to submit ...
Cached Medicine News:Health News:Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers 2Health News:SEIU Endorses AB 8, 'An Opportunity to Make History' 2Health News:Experts Sort Out Good Fats From Bad 2Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program 2
(Date:6/19/2013)... -- Ellen MacArthur Foundation meddelade i ... kommer att vara en partner för att hjälpa ... Efter stiftelsens framgångsrika partnerskap med Renault, BT/Cisco ... att ansluta sig som partner för att få ... verksamhet och stödja stiftelsens arbete inom utbildning. ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance ... alarm fatigue. The need to urgently address this ... its Sentinel Event Alert #50 , "Medical device alarm safety ... database, between January 2008 and June 2012, there were 98 ... resulted in death (82%) , 13 resulted in permanent ...
(Date:6/19/2013)...   BioCision , a leader in advanced ... many areas of medical and scientific research, announced ... U.S. Patent Office that apply to two of ... handling to ensure the consistency of test conditions ... Patent number 8,388,912 covers CoolSink® ...
Breaking Medicine Technology:Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2
... Inc. (Nasdaq: KERX ) today announced that ... from previous clinical trials of Zerenex™ (ferric citrate) were ... the American Society of Nephrology (ASN) Kidney Week 2011 ... ferric iron-based drug candidate, is currently in Phase 3 ...
... and WASHINGTON, Nov. 14, 2011 Nektar Therapeutics (NASDAQ: ... data for NKTR-192, a novel mu-opioid agonist, was presented ... Neuroscience being held November 12-16, 2011 in Washington, DC. ... for the treatment of acute pain.  It is designed ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 2Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 3Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 2Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 3Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 5Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 6
... MacularProtect Complete® is a scientifically ... protection for macular and full body ... the AREDS clinical trial and other ... multinutrient component that provides a broad ...
... formulation that provides the foundation for ... eye-specific nutritional support. All ingredients in ... when applicable. ScienceBased Health formulations are ... bioavailability, and are free of artificial ...
HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
Online Unity Interlaboratory QC Data Management...
Medicine Products: